Plain-English translation of NCT07299019 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing whether a medication called can help slow the worsening of secondary progressive multiple sclerosis. About 990 people will be enrolled and randomly assigned to take either the medication or a placebo (a pill with no active ingredient) every day. The goal is to see if this treatment can reduce disability progression over time.
Secondary progressive multiple sclerosis causes gradual worsening of disability, and people with this form of the disease have limited treatment options available. This trial exists to determine whether this new medication can slow that progression and improve outcomes for patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the medication or a placebo by mouth once daily. The study involves regular clinic visits and check-ins over 2 to 5 years, depending on when you enroll. During the first part of the study, neither you nor the researchers will know whether you're taking the medication or placebo. If you show no worsening after 24 weeks, you may be eligible to switch to open-label treatment where everyone receives the active medication, with the option to continue in a long-term safety study.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States